Why It Matters

Our fund is determined to prevent the next breakthrough technologies from languishing due to the current uncertainty in science funding–instead, we are doubling down and supporting founders who are on the precipice of building the next iconic company.  

“Earning our early SBIRs was a pivotal moment for Recursion. The few million dollars that came in via the SBIR mechanism in our early years allowed us to build the fundamentals of our platform upon which we have now raised over $1B in private investment to turn Recursion into a $4B publicly traded company with eight therapeutics in clinical development.”
— Chris Gibson, Ph.D., Co-founder & CEO of Recursion, Altitude Lab Board Chair

Supporting Underrepresented Founders

With only 15% of SBIR funding and 3% of venture capital going to female and underrepresented founders, the Altitude Lab Funds is committed to ensuring diverse innovators have a chance to build the next great biotech company.

Criteria

Startups are eligible for investment if they:

• Received an SBIR Impact Score of 20 or less in a recent submission. 
  

• Willing to relocate to Altitude Lab in Salt Lake City, Utah for a minimum of 2 years